Article

Four companies receive approval to sell generic ofloxacin

The FDA in May approved an abbreviated new drug application for four companies to manufacture and sell a generic oxfloxacin ophthalmic solution 0.3% for the treatment of bacterial eye infections, including bacterial conjunctivitis and corneal ulcers.

Related Videos
2 experts are featured in this series.
Related Content
Ophthalmology Times 2024 wrap-up: A year of innovation and insight
December 26th 2024

Ophthalmology Times 2024 wrap-up: A year of innovation and insight

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Targeting IL-6 inflammation: A promising frontier in treating thyroid eye disease
December 26th 2024

Targeting IL-6 inflammation: A promising frontier in treating thyroid eye disease

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Exploring electrical stimulation therapy: A promising approach to vision loss in optic neuropathies
Published: December 26th 2024 | Updated: December 26th 2024

Exploring electrical stimulation therapy: A promising approach to vision loss in optic neuropathies

Study: Diabetes does not significantly impact outcomes of epiretinal membrane surgery
Published: December 26th 2024 | Updated: December 26th 2024

Study: Diabetes does not significantly impact outcomes of epiretinal membrane surgery

© 2024 MJH Life Sciences

All rights reserved.